key: cord-0784969-om6yyg4d authors: Farcy, David A; Dalley, Michael T; Miro, Grethel; Swalley, Paige; Sherman, Dana; Nash, Joel; Jodoin, Kathleen; Cubeddu, Luigi X.; Zitek, Tony; Goldszer, Robert title: A Comparison of SARS-CoV-2 Neutralizing Antibody Therapies in High-Risk patients with Mild to Moderate COVID-19 disease at a Single Academic Hospital date: 2021-07-15 journal: J Emerg Med DOI: 10.1016/j.jemermed.2021.07.025 sha: 8b691ebd125f25262fe96714dc48205255ce4f15 doc_id: 784969 cord_uid: om6yyg4d BACKGROUND: Bamlanivimab and casirivimab/imdevimab are recombinant neutralizing monoclonal antibodies which decrease viral load in patients with COVID-19 and may decrease hospitalizations. Little data exist comparing these two therapies. OBJECTIVES: To compare the efficacy and safety of bamlanivimab to casirivimab/imdevimab in emergency department (ED) patients with COVID-19 who meet criteria for monoclonal antibody therapy. METHODS: We performed a single-center, open-label, prospective study in adult ED patients with confirmed COVID-19 and high-risk features for hospitalization. Enrolled patients received bamlanivimab or casirivimab/imdevimab, depending upon the day of the week which they arrived. We observed patients for post-infusion related reactions and contacted them on days 5, 10 and 30. The primary outcome was the number of hospitalizations through day 30. Additionally, we compared groups with regards to return visits to the ED, symptom improvement, antibody-induced adverse events, and deaths. RESULTS: Between December 17, 2020 and January 17, 2021, 321 patients completed the study. We found no statistically significant difference in the rate of subsequent hospitalization between groups: bamlanivimab 18/201 (8.9%) and casirivimab/imdevimab 13/120 (10.8%), p-value = 0.57. Additionally, we found no statistically significant differences between groups regarding return visits to the ED or symptom improvement. One patient had a possible adverse reaction to the treatment, and one patient died. Both of these events occurred in the bamlanivimab group. CONCLUSION: We found no statistically significant differences in rates of subsequent hospitalization or other outcomes for ED patients with COVID-19 when they received bamlanivimab as opposed to casirivimab/imdevimab. Adverse events were rare in both groups. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has created a global pandemic since its emergence in January 2020. Over the course of the last year, multiple therapies have been investigated as potential treatments for patients with COVID-19 [1] [2] [3] [4] [5] [6] [7] . Many of these studies focused on patients with severe COVID-19 requiring hospitalization, of which dexamethasone has shown a mortality benefit 8 . For mild to moderate COVID-19, two recombinant neutralizing monoclonal antibody therapies that target the virus spike protein and subsequent attachment to human ACE-2 receptors, bamlanivimab (LY-CoV555) and casirivimab/imdevimab (REGN-COV2), have shown promise 9, 10 . The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for these therapies for use in mild to moderate COVID-19 within 10 days of symptom onset who are at high risk for progressing to severe COVID-19 and/or hospitalization [11] [12] , and the use of these therapies is already widespread. Although bamlanivimab and casirivimab/imdevimab have shown efficacy in lessening viral load and decreasing hospitalization and emergency department visits 9, 10 , no prospective studies have compared these to therapies to each other. Thus, we now report the findings of a prospective study that compared the efficacy and safety of bamlanivimab to casirivimab/imdevimab for emergency department (ED) patients with mild to moderate COVID-19 who met current criteria for monoclonal antibody therapy. We performed an open-label, prospective, single center, parallel trial, in a cohort of symptomatic (fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shorten of breath on exertion) adult ED patients with COVID-19. The study took place at an academic, tertiary care hospital in Miami Beach. FL with an annual ED volume of approximately 80,000 visits. The study was reviewed and approved by our local institutional review board. All patients provided written informed consent before participating in the study. Patients: Potential study subjects were identified by Emergency Department physicians at the study site and/or referred for eligibility by physicians affiliated with the institution. To be eligible for participation, patients must have been diagnosed with COVID-19 by PCR or a direct antigen test (from our facility or an outside testing facility) and have had one or more mild to moderate symptoms; they must have presented to our hospital within 10 days of symptom onset, and had high-risk features for progressive disease and/or hospitalization. The following were considered high-risk features: age 65 or older, BMI ≥ 35(using patient reported height and weight), diabetes mellitus, chronic kidney disease (GFR < 60 mL per minute per 1.73 m 2 ), and any condition or use of medication that weakens the immune system(such as corticosteroids and immunomodulators). Additionally, patients aged 55 or older with heart disease, high blood pressure, or long-term lung disease were considered to have high-risk features. Patient inclusion started on December 17, 2020 and ended on January 17, 2021. The date of final follow-up was February 16, 2021. Intervention: Enrollment took place from 8a-8p on assigned days. Enrolled patients received either bamlanivimab or casirivimab/imdevimab. The monoclonal antibodies were administered as a single, one-hour, intravenous infusion. Casirivimab and imdevimab were given at 1.2 g each. The bamlanivimab dose was 700 mg. For practicality, selection of therapy received depended on the day of the week the infusion took place. Bamlanivimab was given on Tuesday/Thursday/Saturday/Sunday, and casirivimab/imdevimab was given on Monday/Wednesday/Friday. Prior to receiving the monoclonal antibody infusion, all patients received 25mg of Diphenhydramine and 20 mg of famotidine intravenously (Allergy prophylaxis). A patient care area (pod) in our 50 bed ED was designated for infusion administrations. Infusions were administered from 8a-8p. All patients were observed for one additional hour for potential medication-related reactions. Data Collection: Principal and co-investigators collected the following information at the time of infusion: patient demographics, date of symptom onset, date of positive COVID-19 test results, date of the infusion, symptoms, vital signs, and associated comorbidities. A comorbidity score was generated, with a score of 1 indicating one comorbidity, a score of 2 indicating presence of two comorbidities, etc. On days 5 and 10, Progression of symptoms was assessed via phone calls by Bilingual research assistants and/or co-investigators. If the patient did not answer the initial call, a text message in English and/or Spanish was sent(see Appendix 1) We employed a 1-5 ordinal scale to gather the patients' self-assessment of their well-being at day 5 and 10 post-infusion (see Appendix 1). On day 30, a return to Emergency department visit and/or hospitalization was gathered via phone call and or text messages as well as medical record review. Two co-investigators were responsible for data extraction Outcomes: The primary outcome of the study was the percentage of patients requiring hospitalization within 30 days of the monoclonal antibody treatment in each treatment group. We analyzed these hospitalizations and determined which of these hospitalizations were COVID-19 related (worsening symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shorten of breath on exertion). We also compared the bamlanivimab and casirivimab/imdevimab groups with respect to the total number of return visits to the ED within 30 days, patient reported symptoms (measured on a scale of 1-5) on days 5 and 10 post-infusion, the frequency of monoclonal antibody-induced adverse events, and deaths within 30 days. Statistical Analyses: Results were presented as means (± SD ), median [IQR] or as number of observations and percentages. The Mann Whitney U test was employed to test for differences between medians for ordinal variables, and the unpaired Welch's t-test to assess for differences in mean values of continuous variables. The Fisher exact test and relative risk (95% CI) was used to assess for comparison of binary variables across treatment groups. Confidence intervals in this report were not adjusted for multiplicity. Adjustments for multiple testing were not conducted. Statistical analyses were performed with SSPS software. Using an alpha of 0.05, we calculated that we would need to enroll 140 patients in each group to have 80% power to detect a difference in hospitalization rate of 10% between the two groups. We anticipated approximately a 15% lost to follow up rate, so we planned to enroll at least 322 patients. Between December 17, 2020 and January 17, 2021, we enrolled 327 patients, but 5 were lost to follow up and 1 left against medical advice before data completion. Thus, 321 patients were included for analysis (see Figure 1 ). Among these patients, 39.8% of patients self-identified as females, and 92.8% as White-Caucasians. Nearly half the patients (49.8%) identified their ethnicity as Hispanic. The mean age was 65.0 ± 12.5 years. The mean BMI was 29.9 ± 6.1 kg/m 2 . The median number [IQR] of comorbidities present at baseline was 1 [1-2] (range 1-5). The median [IQR] number of days from symptoms' onset to infusion was 5 [3] [4] [5] [6] [7] . Bamlanivimab was administered to 62.6 % (201/321) and casirivimab/imdevimab to 37.4% (120/321) of the study patients. The two treatment groups were well balanced regarding demographics, risk factors, onset of symptoms, symptom severity, time from diagnosis to infusion therapy (Table 1) . With regards to the primary outcome, there was no statistically significant difference in the percentage of patients who were subsequently hospitalized within 30 days of monoclonal antibody treatment. In particular, 18 of 201 patients (8.9%) who received bamlanivimab and 13 of 120 patients (10.8%) who received casirivimab/imdevimab were subsequently hospitalized (pvalue = 0.57). There were no differences in the baseline values for BMI, comorbidities scores, HR, RR, BP, SpO2 and body temperature between hospitalized and non-hospitalized patients. There was no difference in the median [IQR] number of days that elapsed from symptoms onset to infusion administration for hospitalized 6 [3] [4] [5] [6] [7] , and 4.5 [3] [4] [5] [6] [7] for non-hospitalized patients (P=0.61). Of the 18 hospitalizations in the bamlanivimab group, 13 (72.2%) were considered to be were considered to be COVID-19 related ( Table 2 ). There were no statistically significant differences between the COVID-19 related hospitalization rates between the two groups: bamlanivimab 6.5% and casirivimab/imdevimab 5.8% (p =1.00). There were 46 return visits to the ED (14.3% of all enrolled patients) during the 30 days of the study period, of which 33 (10.3 % of study patients) were considered as COVID-19-related ED visits (worsening symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath on exertion). COVID-related ED visits occurred in 10.4% (21/201) of the patients that received bamlanivimab and in 10.0% (12/120) of the patients that received casirivimab/imdevimab (P>0.99) ( Table 2) . Improvement in symptoms and overall general health were assessed on day 5 and day 10 after monoclonal antibody administration (Table 3 ). There were no significant differences in the selfreported symptoms and health scores between the bamlanivimab arm and the casirivimab/imdevimab arm. Return to pre-COVID-19 health 5 days after infusion was reported in 30.7% and 32.2% of patients treated with bamlanivimab and casirivimab/imdevimab, respectively. Return to pre-COVID-19 health at 10 days after the infusion was reported in 58.3% and 54.7% of patients who received bamlanivimab and casirivimab/imdevimab, respectively (P=0.56) ( Table 3) . Of the 31 patients hospitalized, 30 patients were discharged. One death occurred in a patient who received bamlanivimab (see Appendix 2 for details). A possible infusion-related reaction was reported in 1 subject who received bamlanivimab. See Appendix 2 for details. No deaths or adverse reactions from the infusion occurred in the casirivimab/imdevimab group. Previously published data suggest that bamlanivimab 10 and casirivimab/imdevimab 9 provide benefits in reducing viral load, and may reduce COVID-19-related hospitalizations and medical visits. Although the use of bamlanivimab and casirivimab/imdevimab is already widespread, until now, no prospective study has compared the efficacy and safety of bamlanivimab and casirivimab/imdevimab. In our study, we found no statistically significant differences between the bamlanivimab and casirivimab/imdevimab groups in the number of visits to the ED, need for hospitalization, or symptom improvement. These data suggest comparable outcomes with both antibody treatments. However, further studies in larger number of patients, preferably with a randomized trial are needed to confirm our observations. Regarding monoclonal antibody safety, we observed only one possible medication reaction related to the treatments in this study ---this occurred in a patient who received bamlanivimab. Consistent with prior studies 12,13 this low rate of adverse events indicates that the treatment can be administered outside of a traditional infusion center. Of note, due to increasing SARS-CoV-2 viral variants and their resistance to bamlanivimab, the FDA recently revoked the EUA for bamlanivimab alone, and it is now given in combination with etesevimab. Therefore, the specific treatment (bamlanivimab alone) evaluated in this study is no longer a viable option. It is unclear how the results of this study would have changed had etesevimab been given with bamlanivimab. However, it seems unlikely that the combination of bamlanivimab and etesevimab would be less efficacious than bamlanivimab alone, and additionally, our data suggests that adverse events from casirivimab/imdevimab are rare. Therefore, in the absence of better data, either bamlanivimab/etesevimab or casirivimab/imdevimab seem like reasonable options for patients with COVID-19 who meet criteria for monoclonal antibody therapy. 14 This study has several limitations. First, this study was not randomized. Patients were administered either bamlanivimab or casirivimab/imdevimab based on the day of the week. Although the measured baseline characteristics of the groups were similar, the method of treatment assignment we used may have created unrecognized differences between groups. Additionally, this study did not include a placebo/control group, and thus the results of this study cannot be used to prove the efficacy of monoclonal antibody treatment compared to placebo. While monoclonal antibody therapies have been shown to decrease viral load, the data suggesting benefits for patient-oriented outcomes is less robust. Next, we did not assess for pre-existing immune response and viral load at baseline and after monoclonal antibody infusion therapy. Theoretically, exogenous antibody therapy will have the most benefit in patients whose natural immune response has not been initiated. 8 However; preinfusion immune response screening seems unsuitable for daily practice. Finally, the sample size of this study was too small to detect small differences between groups or to assess for rare adverse events related to monoclonal antibody infusions for COVID-19. We can, however, state that adverse events are rare, and there do not appear to be any large differences in outcomes when using bamlanivimab as opposed to casirivimab/imdevimab. In this prospective study, we found no statistically significant differences in the rate of subsequent hospitalization or other outcomes for patients who received bamlanivimab as compared to casirivimab/imdevimab for mild to moderate COVID-19. Adverse events related to the infusion of the monoclonal antibody medications were rare. Appendix 2 Patient details regarding safety and mortality: Possible infusion-related reaction was reported in 1 subject who received bamlanivimab. The patient returned to the ED the same day with Altered Mental Status (AMS) and somnolence. A stroke evaluation was performed which included a CT scan of the brain which showed no acute findings. The patient's symptoms resolved during observation in the ED and discharged home. The AMS was attributed to the pre-medication (Benadryl and Pepcid) received prior to the monoclonal antibody infusion. (1) Why is this topic important? The use of monoclonal antibody therapies for COVID-19 is now commonplace, but little data exist comparing the two frequently used options: bamlanivimab and casirivimab/imdevimab. (2) What does this study attempt to show? This study attempts to compare the efficacy and safety of bamlanivimab and casirivimab/imdevimab in emergency department patients with mild to moderate Covid-19 and high-risk features for hospitalization. (3) What are the key findings? No statistically significant differences were found between groups with regards to return visits to the emergency department, hospitalizations, or deaths within 30 days. Adverse events related to monoclonal antibody infusions were rare in both groups. (4) How is patient care impacted? For patients with COVID-19 who meet criteria for monoclonal antibody therapy, both bamlanivimab and casirivimab/imdevimab seem to be reasonable options. Table1. Patient demographics, comorbidities and baseline vital signs. HTN denotes hypertension, DM diabetes mellitus, CKD Chronic kidney disease, HIS history of immune suppressive disease and/or treatment with immune-suppressant drugs, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, RR respiratory rate, IQR interquartile range. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Remdesivir for the Treatment of Covid-19 -Final Report Baricitinib restrains the immune dysregulation in patients with severe COVID-19 Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: A case report and literature review Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Metaanalysis Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial Dexamethasone in Hospitalized Patients with Covid-19 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Medical Association A. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19 Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial Patient self-assessment of symptoms improvement was evaluated at day 5 and day 10 after antibody administration. The following three questions were employed Have you returned to your usual (pre-COVID) health today? Have you returned to your usual (pre-COVID) health today? Yes answers (n, %) 5 [4] [5]